Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
42 hedge funds and large institutions have $8.4M invested in Unity Biotechnology in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 1 closing their positions.
8,103% more call options, than puts
Call options by funds: $2.63M | Put options by funds: $32K
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
31% more capital invested
Capital invested by funds: $6.42M → $8.4M (+$1.98M)
17% more funds holding
Funds holding: 36 → 42 (+6)
7.6% more ownership
Funds ownership: 18.32% → 25.93% (+7.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.86M |
| 2 |
AC
Armistice Capital
New York
|
+$1.28M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$90.5K |
| 4 |
Morgan Stanley
New York
|
+$79.7K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$161K |
| 2 |
LCM
Laurion Capital Management
New York
|
-$90.1K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$26.4K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$18.4K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.99K |
UBX Hedge Fund Activity: Q4 2023 in Review
42 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q4 2023, worth a combined $8.4M — up 31% from $6.42M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new UBX positions and 1 closed out — a net gain of 7 holders — while 7 added to existing stakes and 10 trimmed.
The largest buyer was Alyeska Investment Group, adding an estimated $1.86M. The largest seller was UBS O'Connor, cutting an estimated $161K.
- 42 institutional investors held Unity Biotechnology (UBX) as of Q4 2023, up from 36 in Q3 2023.
- Funds reported $8.4M of Unity Biotechnology stock for Q4 2023, up 31% quarter-over-quarter.
- 8 funds opened new Unity Biotechnology positions in Q4 2023 and 1 closed out, a net change of +7 holders.
- The largest Unity Biotechnology buyer in Q4 2023 was Alyeska Investment Group, an estimated $1.86M added.
- The largest Unity Biotechnology seller in Q4 2023 was UBS O'Connor, an estimated $161K sold.
Based on aggregated 13F filings for Q4 2023.